Dashboard
Manage Tickers

PLRX PLIANT THERAPEUTICS, INC.

Nasdaq pliantrx.com


$ 1.57 $ -0.08 (-4.85 %)    

Friday, 17-Oct-2025 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.57
$ 1.65
$ 1.55 x 2
$ 1.75 x 100
$ 1.55 - $ 1.70
$ 1.10 - $ 16.10
378,357
na
96.38M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-downgrades-pliant-therapeutics-to-underweight
JP Morgan Downgrades Pliant Therapeutics t...
10/10/2025 11:36:28

JP Morgan analyst Brian Cheng downgrades Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Underweight.

piper-sandler-maintains-overweight-on-pliant-therapeutics-lowers-price-target-to-4
Piper Sandler Maintains Overweight on Plia...
08/08/2025 11:28:12

Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price targ...

pliant-therapeutics-q2-eps-071-inline
Pliant Therapeutics Q2 EPS $(0.71), Inline
08/07/2025 20:56:57

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
06/27/2025 21:05:51

pliant-therapeutics-discontinues-development-of-bexotegrast-in-idiopathic-pulmonary-fibrosis-after-beacon-ipf-phase-2b3-clinical-trial-review
Pliant Therapeutics Discontinues Developme...
06/27/2025 20:12:52

Bexotegrast development in IPF discontinuedClinical oncology program and early-stage programs continueRecent workforce and oper...

pliant-therapeutics-announces-the-company-led-oral-and-poster-presentations-of-clinical-and-preclinical-data-this-week-as-part-of-the-american-thoracic-society-2025-international-conference
Pliant Therapeutics Announces The Company ...
05/21/2025 20:05:43

Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company led oral and poster presentations of clinical and prec...

pliant-therapeutics-q1-eps-092-misses-074-estimate
Pliant Therapeutics Q1 EPS $(0.92) Misses ...
05/08/2025 21:03:48

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
05/05/2025 12:07:17

pliant-therapeutics-announces-strategic-restructuring-reduces-workforce-by-45
Pliant Therapeutics Announces Strategic Re...
05/01/2025 20:12:40

hc-wainwright--co-reiterates-neutral-on-pliant-therapeuticsto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
03/18/2025 15:53:59

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Neutral.

pliant-therapeutics-investigational-cancer-drug-shows-antitumor-activity-across-multiple-tumor-types
Pliant Therapeutics' Investigational Cance...
03/17/2025 17:39:53

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose teste...

pliant-therapeutics-announces-interim-phase-1-data-fro-first-three-of-five-potential-cohorts-of-phase-1-dose-escalation-trial-of-pln-101095-says-antitumor-activity-observed-with-confirmed-partial-responses-in-50-of-patients
Pliant Therapeutics Announces Interim Phas...
03/17/2025 12:08:06

pliant-therapeutics-adopts-limited-duration-stockholder-rights-agreement-in-response-to-recent-accumulations-of-its-common-stock
Pliant Therapeutics Adopts Limited Duratio...
03/13/2025 11:23:21

The Rights Agreement will expire on March 11, 2026, or earlier, as provided in the Rights Agreement.Under the Rights Agreement,...

pliant-therapeutics-drops-ipf-drug-trial-after-review-analyst-flags-uncertain-future
Pliant Therapeutics Drops IPF Drug Trial A...
03/04/2025 18:37:13

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts...

hc-wainwright--co-reiterates-neutral-on-pliant-therapeuticsto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
03/04/2025 17:28:03

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Neutral.

citigroup-maintains-neutral-on-pliant-therapeutics-lowers-price-target-to-15
Citigroup Maintains Neutral on Pliant Ther...
03/04/2025 17:15:43

Citigroup analyst David Lebowitz maintains Pliant Therapeutics (NASDAQ:PLRX) with a Neutral and lowers the price target from...

rbc-capital-maintains-sector-perform-on-pliant-therapeutics-lowers-price-target-to-3
RBC Capital Maintains Sector Perform on Pl...
03/04/2025 15:30:41

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Sector Perform and lowers the price ta...

this-teleflex-analyst-turns-bearish-here-are-top-5-downgrades-for-tuesday
This Teleflex Analyst Turns Bearish; Here ...
03/04/2025 14:38:16

cantor-fitzgerald-reinstates-neutral-on-pliant-therapeutics
Cantor Fitzgerald Reinstates Neutral on Pl...
03/04/2025 14:29:12

Cantor Fitzgerald analyst Pete Stavropoulos reinstates Pliant Therapeutics (NASDAQ:PLRX) with a Neutral.

wells-fargo-maintains-equal-weight-on-pliant-therapeutics-lowers-price-target-to-3
Wells Fargo Maintains Equal-Weight on Plia...
03/04/2025 13:32:29

Wells Fargo analyst Tiago Fauth maintains Pliant Therapeutics (NASDAQ:PLRX) with a Equal-Weight and lowers the price target ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION